unfortunately i can't listen to the call. I reall
Post# of 148168
During 2021, your common shareholders sustained a loss of over 80% on their investment, despite numerous new trials and seemingly positive news on the science for Leronlimab.
What is the plan in 2022 to restore value to common shareholders?